Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
24 Fevereiro 2022 - 10:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary, Pasithea Clinics, has expanded its treatment offerings
and is planning to open three new clinics in London to treat
patients suffering from mental health issues. The Company already
has locations in Marylebone and Knightsbridge.
“With these new clinics, we will broaden our
London footprint and start offering pharmacy services and new
treatment options, bringing important and novel mental health
therapies to an ever-growing number of people. In addition to
pharmacy services, our London clinics will offer other psychiatric
treatment therapies, including repeated transcranial magnetic
stimulation and ketamine and esketamine treatment,” stated Dr.
Tiago Reis Marques, CEO of Pasithea Therapeutics. “With our strong
cash position and our continued expansion in London, we believe we
are well positioned to bring value to our shareholders,” concluded
Dr. Marques.
“We are excited to expand our partnership with
ZEN Healthcare, which has been providing pioneering IV therapies in
London for six years. By offering more locations, and a greater
number of treatment options, we continue to work toward closing the
treatment gap and getting millions of people the help they need,”
said Dr. Yassine Bendiabdallah, Managing Director of Pasithea
Clinics in the UK.
The clinics, which will be operated by Pasithea,
with management support from ZEN Healthcare, are expected to open
by mid-2022. Each clinic will contribute an estimated USD$5 million
annually in revenue.
Repeated transcranial magnetic stimulation
(“rTMS”) is a therapeutic brain-stimulation technique based on the
principle of electromagnetic induction. First developed in 1985,
rTMS has been studied as a treatment for depression, psychosis,
anxiety, and other mental health conditions, and has shown
particular efficacy with drug-resistant depressive disorders. In
2008, rTMS was approved for use by the FDA as a treatment for major
depression for patients who do not respond to at least one
antidepressant medication. A typical plan consists of five
treatments per week over the course of four to six weeks.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced to the medical community as an
anesthetic more than 50 years ago. It has recently been repurposed
for the treatment of psychiatric disorders using significantly
lower doses than in anesthesia and is gaining ground as a promising
treatment for mental health disorders. In certain psychiatric
conditions, such as treatment-resistant depression (“TRD”) and
post-traumatic stress disorder (“PTSD”), it has shown remarkable
efficacy and a rapid and sustained effect. While the number of
treatments suggested is done on a case-by-case basis, a typical
treatment plan consists of up to six infusions in the interval of
two to three weeks.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
About ZEN Healthcare
ZEN Healthcare is a luxury pharmacy and health
clinic in London with three branches – Baker Street, Knightsbridge
and Holborn. The clinics comprise a multidisciplinary group of
Private GPs, anti-ageing doctors, pharmacists, nutritionists,
dermatologists and psychotherapists, as well as intravenous
infusions specialists. ZEN Healthcare has been running pioneering
IV therapies in London for six years.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
ContactDr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024